InsiderTrades.com logo
James M. Frates net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

James Frates Biography and Net Worth

CFO of Amylyx Pharmaceuticals

Jim Frates serves as Amylyx’s Chief Financial Officer, having previously been the CFO of Alkermes for 22 years. Prior to working at Alkermes, Jim was a Vice President in the Life Sciences Practice at Robertson Stephens & Company. He currently serves on the board of directors of Sage Therapeutics and is a Trustee of St. Francis House, the largest homeless day shelter in Massachusetts. Jim earned a Bachelor of Arts in Government from Harvard College and a Master of Business Administration from the Harvard Graduate School of Business Administration.

What is James M. Frates' net worth?

The estimated net worth of James M. Frates is at least $7.15 million as of September 10th, 2026. Frates owns 233,625 shares of Amylyx Pharmaceuticals stock worth more than $7,148,925 as of September 24th. This net worth evaluation does not reflect any other investments that Frates may own. Learn More about James M. Frates' net worth.

How do I contact James M. Frates?

The corporate mailing address for Frates and other Amylyx Pharmaceuticals executives is 55 Cambridge Parkway, Suite 6w, Cambridge, MA, 02142. Amylyx Pharmaceuticals can also be reached via phone at 617-682-0917 and via email at [email protected]. Learn More on James M. Frates' contact information.

Has James M. Frates been buying or selling shares of Amylyx Pharmaceuticals?

Over the course of the past ninety days, James M. Frates has sold $349,811.60 in shares of Amylyx Pharmaceuticals stock. Most recently, James M. Frates sold 10,810 shares of the business's stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $32.36, for a transaction totalling $349,811.60. Following the completion of the sale, the chief financial officer now directly owns 233,625 shares of the company's stock, valued at $7,560,105. Learn More on James M. Frates' trading history.

Who are Amylyx Pharmaceuticals' active insiders?

Amylyx Pharmaceuticals' insider roster includes Camille Bedrosian (Insider), Joshua Cohen (Co-Founder), Joshua Cohen (CEO), Karen Firestone (Director), James Frates (CFO), M Jr (Director), Justin Klee (CEO), Justin Klee (Co-Founder), Gina Mazzariello (Insider), Daphne Quimi (Director), Patrick Yeramian (Insider), and Bernhardt Zeiher (Director). Learn More on Amylyx Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Amylyx Pharmaceuticals?

In the last year, Amylyx Pharmaceuticals insiders bought shares 1 times. They purchased a total of 8,100 shares worth more than $100,845.00. In the last year, insiders at the sold shares 15 times. They sold a total of 294,490 shares worth more than $4,701,360.02. The most recent insider tranaction occured on September, 10th when insider Camille L Bedrosian sold 10,028 shares worth more than $324,907.20. Insiders at Amylyx Pharmaceuticals own 10.9% of the company. Learn More about insider trades at Amylyx Pharmaceuticals.

Information on this page was last updated on 9/10/2026.

James M. Frates Insider Trading History at Amylyx Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2026Sell10,810$32.36$349,811.60233,625View SEC Filing Icon  
1/6/2026Sell3,326$11.11$36,951.86177,104View SEC Filing Icon  
9/30/2025Sell10,558$14.65$154,674.70280,430View SEC Filing Icon  
3/31/2025Sell10,896$3.47$37,809.12290,988View SEC Filing Icon  
9/12/2024Buy40,000$2.53$101,200.00233,464View SEC Filing Icon  
3/5/2024Sell1,792$18.73$33,564.16134,784View SEC Filing Icon  
1/9/2024Sell2,716$16.33$44,352.28112,035View SEC Filing Icon  
5/16/2023Sell32,500$26.94$875,550.0055,676View SEC Filing Icon  
3/16/2023Sell32,500$31.89$1,036,425.001,509View SEC Filing Icon  
See Full Table

James M. Frates Buying and Selling Activity at Amylyx Pharmaceuticals

This chart shows James M. Frates's buying and selling at Amylyx Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Amylyx Pharmaceuticals Company Overview

Amylyx Pharmaceuticals logo
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.
Read More

Today's Range

Now: $30.60
Low: $30.53
High: $33.02

50 Day Range

MA: $28.06
Low: $17.02
High: $39.66

2 Week Range

Now: $30.60
Low: $10.83
High: $41.14

Volume

1,824,848 shs

Average Volume

1,609,611 shs

Market Capitalization

$3.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A